Oral clodronate in breast cancer patients with bone metastases: a randomized study
Authors:
- 1 July 1999
- journal article
- clinical trial
- Published by Wiley in Journal of Internal Medicine
- Vol. 246 (1) , 67-74
Abstract
Objectives. To investigate the effect of the bisphosphonate clodronate on the occurrence of skeletal events (hypercalcaemia, fractures and radiotherapy) in breast cancer patients with bone metastases.Design. Prospective, randomized, controlled, clinical trial.Setting. A department of oncology in a university hospital.Subjects. One hundred patients who received first‐line systemic antineoplastic treatment for metastatic breast cancer with bone involvement were randomized to receive clodronate as two 400 mg capsules twice a day for 2 years or no additional therapy.Results. In the clodronate group the number of skeletal events was reduced to 14 events in 48 evaluable patients as compared with 21 events in 51 evaluable control patients. The time to the first skeletal event was significantly longer in the clodronate group than in the control group (P = 0.015) and the most distinct difference was a lower occurrence of fractures in the clodronate group (P = 0.023). After 15 months the effect of clodronate tended to decline as the need for radiotherapy increased in the clodronate group compared with the control group (P = 0.069). Significant improvements in several quality‐of‐life aspects were seen in both groups during the first 6 months, but there was no significant difference between the groups. No effect was observed on time to radiologically evaluated disease progression in bone or on survival. The most frequent side‐effects resulting in discontinuation of clodronate were nausea and diarrhoea.Conclusion. Oral clodronate is associated with a temporary reduction of morbidity related to bone metastases in breast cancer patients.Keywords
This publication has 12 references indexed in Scilit:
- Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate TreatmentNew England Journal of Medicine, 1998
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Clodronate decreases the frequency of skeletal metastases in women with breast cancerBone, 1996
- Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.Journal of Clinical Oncology, 1996
- Events per person year—a dubious conceptBMJ, 1995
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- Palliative pamidronate treatment in patients with bone metastases from breast cancer.Journal of Clinical Oncology, 1993
- Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.Journal of Clinical Oncology, 1993
- Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized studyJournal of Internal Medicine, 1992
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983